Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13226889 | 0.81 | RAB9A (0.55) | GFERRAB9ANPC1MEN1KMT2A | |
| SCHEMBL1224649 | 0.80 | RAB9A (0.53) | GFERRAB9ANPC1MEN1KMT2A | |
| SCHEMBL12776290 | 0.79 | RAB9A (0.52) | GFERRAB9ANPC1MEN1KMT2A | |
| SCHEMBL12776319 | 0.76 | RAB9A (0.50) | GFERRAB9ANPC1MEN1KMT2A | |
| SCHEMBL12844032 | 0.75 | PIK3CD (0.56) | GFERPIK3CDRAB9ANPC1L3MBTL1 | |
| SCHEMBL12776298 | 0.75 | RAB9A (0.66) | GFERRAB9ANPC1MEN1KMT2A | |
| SCHEMBL12776391 | 0.73 | RAB9A (0.53) | GFERRAB9ANPC1MEN1KMT2A | |
| SCHEMBL425355 | 0.71 | TSHR (0.43) | PIK3CDMEN1KMT2AL3MBTL1CYP2D6 | |
| SCHEMBL1303006 | 0.71 | PIK3CD (1.00) | PIK3CDMEN1KMT2ACYP2D6 | |
| SCHEMBL2755782 | 0.70 | PIK3CD (0.88) | PIK3CDKMT2AL3MBTL1CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | GFER 1501/4885PIK3CD 2152/4885RAB9A 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.